*All times Eastern Standard Time*

7:45 am Conference Registration & Networking

8:55 am Chair’s Opening Remarks

Navigating NASH: What do we Know Now & How Have we Got Here?

9:00 am NASH Monotherapy: A Tour of the FXR Agonist Menagerie

9:30 am Using Single Cell Genomics to Investigate the Fibrotic Niche in Human Liver Cirrhosis

  • Neil Henderson Professor of Tissue Repair and Regeneration, University of Edinburgh

10:00 am Speed Networking Session One

10:40 am Morning Break & Networking

12:45 pm Lunch Break & Networking

3:30 pm Afternoon Break & Networking

Tackling Translation: How we’ve Progressed & How Far we Have to go

4:00 pm The End of the Beginning in NASH Therapy; Ongoing Challenges (Key Note)

  • Scott Friedman Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases, Icahn School of Medicine at Mount Sinai

4:30 pm Siemens Enhanced Liver Fibrosis (ELF) Test – Its Rationale & an Update on its Utility

  • Andrew Beard Head of Business Development & Partnering , Siemens Healthineers

Should we Consider NASH the Liver Manifestation of Diabetes & Employ a More Systemic Approach to Targeting Disease?

5:00 pm Insulin Sensitizing Pharmacology as a Treatment for NASH

  • Jerry Colca Chief Scientific Officer, Cirius Therapeutics

5:30 pm Dual GLP-1 Agonists in the Treatment Metabolic & Liver Dysfunction in NASH

6:00 pm Panel Discussion: Is the Cure for NASH Better Treatment of Obesity?

  • Scott Harris Chief Medical Officer, Altimmune
  • Jerry Colca Chief Scientific Officer, Cirius Therapeutics
  • Scott Friedman Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases, Icahn School of Medicine at Mount Sinai
  • Peter Traber Partner, Alacrita Consulting

6:30 pm Conference Day One Ends